Binimetinib

Binimetinib is a selective MEK1/2 inhibitor used in combination with encorafenib for the treatment of BRAF-mutant melanoma. Simson Pharma's Binimetinib reference standard and impurities support stability-indicating method development for this targeted combination oncology therapy.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Binimetinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.

Pharmaceutical Reference Standards / Impurity Standards

Binimetinib
N-desmethyl Binimetinib
Binimetinib Acid Impurity
Binimetinib Des Ethanediol Impurity
Binimetinib Methyl Ester
Binimetinib Impurity 20
Binimetinib N-Oxide
Binimetinib Dimer Impurity
Binimetinib Ethyleneglycol Ester
Binimetinib Impurity 2
Binimetinib Impurity 1
Binimetinib Cyclized impurity
Binimetinib Impurity 11
Binimetinib Des Bromo Impurity
Binimetinib Des Bromo Acid Impurity
Binimetinib Des Bromo Vinyloxy Impurity
Binimetinib Ethyl Ether Impurity
Binimetinib Impurity 10
Binimetinib Impurity 16
Binimetinib Impurity 17
Binimetinib Impurity 18
Binimetinib Impurity 19
Binimetinib Dibromo Impurity
N-Nitroso Binimetinib
N-Nitroso N-Desmethyl Binimetinib
Binimetinib Acid Nitroso Impurity
Binimetinib Nitroso Amide Impurity
N-Nitroso Binimetinib Impurity 1
Binimetinib Impurity 3
Binimetinib Impurity 4
N-Nitroso Des Ethanediol Impurity
Binimetinib Amide Impurity
Binimetinib Impurity 5
Binimetinib Impurity 6

Metabolites

N-Desmethyl Binimetinib Hydrochloride
Binimetinib Glucuronide

Isotope Labelled Compounds

Binimetinib 13C2-D4